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Summary
Skeletal aging results in apoptosis of osteocytes, cells embedded
in bone that control the generation/function of bone forming
and resorbing cells. Aging also decreases connexin43 (Cx43)
expression in bone; and osteocytic Cx43 deletion partially mimics
the skeletal phenotype of old mice. Particularly, aging and Cx43
deletion increase osteocyte apoptosis, and osteoclast number
and bone resorption on endocortical bone surfaces. We examined
herein the molecular signaling events responsible for osteocyte
apoptosis and osteoclast recruitment triggered by aging and
Cx43 deficiency. Cx43-silenced MLO-Y4 osteocytic (Cx43def) cells
undergo spontaneous cell death in culture through caspase-3
activation and exhibit increased levels of apoptosis-related
genes, and only transfection of Cx43 constructs able to form
gap junction channels reverses Cx43def cell death. Cx43def cells
and bones from old mice exhibit reduced levels of the pro-
survival microRNA miR21 and, consistently, increased levels of
the miR21 target phosphatase and tensin homolog (PTEN) and
reduced phosphorylated Akt, whereas PTEN inhibition reduces
Cx43def cell apoptosis. miR21 reduction is sufficient to induce
apoptosis of Cx43-expressing cells and miR21 deletion in miR21fl/fl
bones increases apoptosis-related gene expression, whereas a
miR21 mimic prevents Cx43def cell apoptosis, demonstrating that
miR21 lies downstream of Cx43. Cx43def cells release more
osteoclastogenic cytokines [receptor activator of NFjB ligand
(RANKL)/high-mobility group box-1 (HMGB1)], and caspase-3
inhibition prevents RANKL/HMGB1 release and the increased
osteoclastogenesis induced by conditioned media from Cx43def
cells, which is blocked by antagonizing HMGB1-RAGE interaction.
These findings identify a novel Cx43/miR21/HMGB1/RANKL
pathway involved in preventing osteocyte apoptosis that also
controls osteoclast formation/recruitment and is impaired with
aging.
Key words: aging; apoptosis; connexin43; HMGB1; miR21;
osteocyte.
Introduction
Increasing evidence suggests that the viability of osteocytes embedded
within the bone mineral matrix is essential for maintaining skeletal
homeostasis, as supported by the increase in apoptotic osteocytes and
prevalence of empty lacunae observed in conditions of elevated bone
fragility and with old age (Plotkin & Bellido, 2016). Osteocytes have long
dendritic processes that create an extensive network allowing for
communication between adjacent osteocytes and with osteoblasts and
osteoclasts on the bone surface, and disruption of this network impairs
osteocytic regulation of bone formation and resorption (Bonewald,
2011). Osteocyte interactions with other cells occur through the release
of cytokines to the lacunar–canalicular system that surrounds osteocytes,
as well as through cell-to-cell communication via gap junction channels
(Plotkin & Bellido, 2013). Previous work from our group has demon-
strated that the gap junction protein connexin43 (Cx43) is a critical
component of the signaling pathway controlling osteocyte survival, as
evidenced by the increased osteocyte apoptosis in mice lacking Cx43 in
osteoblasts and osteocytes or only in osteocytes (Plotkin et al., 2008; Bivi
et al., 2012). In addition to increased osteocyte apoptosis, mice lacking
osteocytic Cx43 (Cx43DOt) exhibit enhanced endocortical resorption,
partially mimicking the phenotype of old mice (Almeida et al., 2007b)
and raising the possibility that decreased Cx43 contributes at least in part
to the skeletal phenotype of aging. However, while it has been shown
that Cx43 levels in osteocytes are decreased in old mice (Kar et al.,
2013), the signaling pathway activated by Cx43 deficiency involved in
osteocyte apoptosis with aging is not known.
One of the potential molecules that could mediate osteocyte
apoptosis is microRNAs (miRs), single-stranded noncoding RNAs that
negatively regulate gene expression (Peng et al., 2016). miRs are
involved in cancer cell survival, and in particular, the expression of
miR21 is upregulated in a variety of cancers, promoting cell survival
through the direct inhibition of apoptotic genes including phosphatase
and tensin homolog (PTEN) (Garzon et al., 2009). In bone, miRs play an
important role in controlling the function and lifespan of both
osteoclasts and osteoblasts (He et al., 2009). However, the role of miRs
on osteocyte apoptosis has not been investigated.
Several models of increased osteocyte death, including ovariectomy,
unloading, microdamage, and a transgenic model of osteocyte apoptosis
induced by diphtheria toxin, exhibited co-localization of apoptotic
osteocytes and osteoclasts, suggesting that signals released by dying
osteocytes induce osteoclast recruitment (Aguirre et al., 2006; Tatsumi
et al., 2007; Cardoso et al., 2009; Emerton et al., 2009). However, the
nature of these signals remains unknown. In osteocytes and other cells,
apoptotic cell death results in the release of the pro-inflammatory
cytokine high-mobility group box-1 (HMGB1), a nonhistone nuclear
DNA-binding protein responsible for stabilization of nucleosomal
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structures facilitating gene transcription (Charoonpatrapong et al.,
2006; Yang et al., 2008). HMGB1 released from the cells activates the
receptor for advanced glycation end products (RAGE) and Toll-like
receptor 4 (TLR4) and can regulate recruitment and differentiation of
osteoclast precursors (Zhou et al., 2008; Yang et al., 2013). However,
whether HMGB1 is involved in osteoclast recruitment and differentiation
induced by apoptotic osteocytes is not known.
Based on the results of this study, we propose that miR21 lies
downstream of Cx43 in the control of osteocyte viability, and that
increased osteocyte apoptosis in the absence of Cx43 and with aging is a
consequence of disruptions in the PTEN/pAkt pathway and reduced
response to the insulin-like growth factor 1 (IGF-1). Further, the
increased osteoclastogenic potential of Cx43-deficient osteocytes is a
result of elevated release of the cytokines RANKL and HMGB1 during
apoptosis, and the subsequent activation of RAGE on osteoclast
progenitors. In conclusion, our data identify a novel Cx43/miR21/
HMGB1/RANKL pathway mediated by gap junction communication in
osteocytes that could be targeted to treat bone fragility in aging.
Results
Aging and Cx43 deficiency result in increased osteocyte
apoptosis
Bones from 24-month-old mice exhibited a decrease in Cx43 mRNA
levels compared to 4-month-old mice (Fig. 1A), and 21-month-old mice
exhibited a 95% decrease in Cx43 protein levels, compared to young,
3.5-month-old mice (Fig. 1B). Consistent with the increased osteocyte
apoptosis reported in old humans and mice (Qiu et al., 2002; Almeida
et al., 2007b), bones (without bone marrow) from 21-month-old mice
exhibit increased expression of apoptosis-related genes (Fig. 1C). To
further study the connection between reduced Cx43 levels and
osteocyte apoptosis, we used an in vitro system in which Cx43 was
silenced in osteocytic and osteoblastic cells. Silencing Cx43 in MLO-Y4
osteocytic and Ob-6 osteoblastic cells using shRNA resulted in a
significant reduction in mRNA levels (Fig. 1D), and ~ 70% and 60%
reduction at the protein level respectively, compared to cells treated with
scramble shRNA (Fig. 1E). Decreased Cx43 expression led to increased
cell death in culture over time in MLO-Y4 osteocytic cells, as previously
shown (Bivi et al., 2012). Cx43 deficiency does not increase osteoblast
apoptosis in vivo, and, similarly, silencing Cx43 in Ob-6 osteoblastic cells
did not alter viability, compared to scramble shRNA-treated cells
(Fig. 1F). Cell death in MLO-Y4 osteocytic cells lacking Cx43 was
reversed by DEVD treatment, an irreversible active caspase-3 inhibitor,
indicating cell death by apoptosis (Fig. 1G). Furthermore, mRNA levels of
FoxO3, p27, and GADD153 genes involved with apoptosis (Zhang et al.,
2011) were increased in MLO-Y4 Cx43-silenced cells (Fig. 1H) but
unaltered in Ob-6 cells (Fig. S1A). Consistent with this, protein levels for
GADD153 and for the apoptosis marker active caspase-3 were increased
in Cx43-deficient cells (Fig. 1I).
We next investigated the domain of Cx43 required to maintain cell
viability. As expected, expression of full-length Cx43 decreased apoptosis
in Cx43-silenced MLO-Y4 cells (Figs 1J and S1B). Similarly, Cx43D245,
lacking the C-terminus scaffold domain, as well as simultaneous
transfection with Cx43D245 and the C-terminus domain (C-tail), which
reassemble to form a complete connexin molecule in the cell (Hoshi
et al., 1990), reversed the increase in apoptosis. On the other hand, the
Cx43D245 mutant is not able to confer responsiveness to bisphospho-
nates or to PTH (Plotkin et al., 2002; Bivi et al., 2011). Cx43-silenced
cells expressing the Cx43 C-tail alone or Cx43Cys-less, a mutant that due
to the lack of cysteine residues in the extracellular domain (Dahl et al.,
1991) only forms hemichannels and it is unable for form gap junctions
(Bao et al., 2004; Tong et al., 2007), maintained an elevated percentage
of apoptosis, similar to vector-transfected cells. This contrasts with the
reversal of the effect of Cx43 silencing in osteoblastic cells by the same
Cx43Cys-less mutant (Bivi et al., 2011). While the experiment reported in
Fig. 1J shows that only constructs with intact intercellular communica-
tion are able to reverse the increase in cell apoptosis in the absence of
Cx43, the experiment of Fig. S1B (Supporting information) shows that
expression of the mutant that can only form hemichannels (Cys-less) and
the C-tail alone partially reduced apoptosis in Cx43-deficient cells. This
discrepancy could be due to different levels of expression of the
construct in the transient transfections or to the different endpoints
evaluated in each experiment. Expression of Cx43D130, a mutant that
lacks channel permeability (Krutovskikh et al., 1998), not only did not
reverse the increase in cell death, but further increased apoptosis,
compared to Cx43-silenced cells transfected by empty vector.
Decreased Cx43 expression reduces miR21, promoting
osteocyte apoptosis
We next examined whether increased apoptosis was associated with
dysregulation of miRs in Cx43-deficient osteocytic cells. Screening of
apoptosis-associated miRNAs revealed a decrease in the levels of miR21,
which promotes survival in various cell types (Garzon et al., 2009) but is
of unknown function in osteoblastic cells (Fig. 2A). On the contrary,
miR218, a pro-apoptotic miR, was expressed at higher levels in Cx43-
deficient MLO-Y4 cells, compared to cells treated with scramble shRNA.
Changes in the expression were confirmed by qPCR, which showed that
miR21 is decreased by 50% whereas miR218 is increased by 500% in
Cx43-deficient osteocytic cells (Fig. 2B). Consistent with increases in
miR218, expression of its target IjB kinase B was reduced (not shown).
On the other hand, silencing Cx43 did not alter the levels of miR21,
miR218 (Fig. 2C), or IjB kinase B (not shown) in Ob-6 osteoblastic cells.
Fig. 1 Aging and deletion of Cx43 in MLO-Y4 osteocytic cells leads to increased apoptosis. (A) Cx43 mRNA levels in calvaria from 4- to 24-month-old mice measured by
qPCR and corrected by GAPDH (Cx43 n = 5–9). (B) Cx43 protein levels in L5 vertebra from mice at 3.5 and 21 months of age were assessed by Western blotting and
normalized by b-actin (n = 6–7). (C) mRNA levels for the indicated apoptosis-associated genes in tibia from young and old mice. (D) Cx43 protein expression was measured
in MLO-Y4 osteocytic (n = 6–9) and Ob-6 (n = 3) expressing (scramble) or lacking (shRNA) Cx43 by qPCR and corrected by GAPDH. (E) Cx43 protein expression was
measured in MLO-Y4 osteocytic and Ob-6 osteoblastic cells by Western blot analysis and normalized by b-actin (n = 4). (F) Cell death assessed in MLO-Y4 osteocytic cells
(n = 3) and in Ob-6 cells (n = 6) expressing or not Cx43 by Trypan blue uptake after culturing them for the indicated times. (G) MLO-Y4 osteocytic cells silenced or not for
Cx43 were treated for 1 or 24 h with DEVD and percentage of cells undergoing cell death were assessed by Trypan blue uptake (n = 6). (H) Gene expression was measured
by qPCR and corrected by GAPDH (n = 6–9). (I) Protein expression for GADD153 and active caspase-3 assessed by Western blotting (n = 4). (J) MLO-Y4 osteocytic cells were
transiently transfected with empty vector or the indicated Cx43 constructs together with nGFP. Apoptosis was determined by evaluating nuclear morphology of the
transfected (green fluorescent) cells. A representative image of cells exhibiting nuclear fragmentation (arrow) compared to other cells with normal morphology is shown.
Bars and dots represent mean  SD. *P < 0.05 vs. 4 months of age, by one-way ANOVA (A), *P < 0.05 vs. young (B and C) or vs. scramble shRNA cells (D-I), by t-test.
*P < 0.05 vs. vector-transfected scramble shRNA cells, #P < 0.05 vs. vector-transfected Cx43 shRNA cells by one-way ANOVA (J).
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In addition, 24-month-old mice exhibited a decrease in miR21 levels,
compared to young mice, similar to Cx43def cells. The expression of
miR218 was not significantly changed in the bones from aging mice,
although it showed a tendency toward increase in 18-month-old mice
(Fig. 2D). Furthermore, Cx43DOt mice lacking Cx43 in osteocytes exhibit
reduced miR21 levels; however, miR218 and IjB kinase B were not
altered (Fig. 2E).
Reduced miR21 levels lead to osteocytic cell death and
increased PTEN levels in bone
Similar to silencing the Cx43 gene, reduction of miR21 expression by
transfecting a specific oligonucleotide inhibitor induced apoptosis of
control osteocytes, whereas transfection of a miR21-mimic
oligonucleotide resulted in lower levels of dead cells in scramble-
transfected cells (Fig. 3A). Further, miR21 mimic reversed the increased
apoptosis of Cx43-deficient osteocytes. To further assess the role of
miR21 on bone cell apoptosis, neonatal calvaria bone from miR21fl/fl
mice was treated with adenovirus-Cre to delete the miR21 gene, and
compared to bone treated with adenovirus-GFP as control (Fig. 3B–E).
Addition of adenovirus-Cre resulted in a 91% reduction of miR21 levels
(Fig. 3B). Ultrastructural analysis of osteocytes using transmission elec-
tron microscopy revealed that adenovirus-Cre-treated calvariae from
miR21fl/fl mice exhibited abundant empty lacunae (Fig. 3C). Further-
more, osteocytes, when present, exhibited swollen endoplasmic reticu-
lum, an indicator of cellular stress when compared to calvaria bones
infected with adenovirus-GFP. Similar to Cx43-deficient cells, bones with
deleted miR21 exhibited increased expression of the apoptosis-related
Fig. 2 Cx43 deficiency and old age results in decreased miR21 expression. (A) Profile of 48 apoptosis-associated miRNA assessed in MLO-Y4 osteocytic cells expressing or
not for Cx43 using an miRNA plate array and corrected by U6 RNA (n = 3). (B) Changes in the expression of miR21 and miR218 in MLO-Y4 osteocytic cells were validated by
qPCR and corrected by miR135 (n = 3). (C) Expression of miR21 and miR218 corrected by miR135 in Ob-6 osteoblastic cells (n = 3). (D) miRNA expression in calvaria from 4-
to 24-month-old mice measured by qPCR and corrected by miR135 (n = 5–9). Bars represent mean  SD. #P < 0.05 vs. 12 months of age, by one-way ANOVA. (E) Gene
and miRNA expression in calvaria from Cx43fl/fl and Cx43DOt mice measured by qPCR and corrected by miR135 (miR21 and miR218) or GAPDH (Ikb kinase B). Bars represent
mean  SD (n = 5–8). *P < 0.05 vs. Cx43fl/fl mice, by t-test.
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genes FoxO3 and p27, and a tendency toward increased GADD153
levels (Fig. 3D). Moreover, protein levels of the miR21 target phos-
phatase PTEN were increased by ~ 2.7-fold (Fig. 3E).
Cx43 deficiency and aging result in disruptions in PTEN/pAkt
pathway
Consistent with the decrease in miR21 expression, protein levels of
PTEN were increased 2.4-fold in Cx43DOt compared to Cx43fl/fl mice
(Fig. 4A). Further, reduction of Cx43 expression in MLO-Y4 osteocytic
cells resulted in increased levels of the phosphatase PTEN and
decreased phosphorylated Akt, a known target of PTEN (Fig. 4B,C).
Cell death was blocked by the PTEN inhibitor SF1670 (Fig. 4D,E),
adding support for a role of the phosphatase on cell death induced by
Cx43 deficiency.
We next examined whether the pro-survival effect of IGF-1, which is
mediated by Akt phosphorylation in several cell types, requires Cx43
expression. Because IGF-1 does not decrease the low level of cell death in
vehicle-treated control cells, we induced apoptosis with the synthetic
glucocorticoid dexamethasone, as previously reported (Plotkin et al.,
2007). IGF-1 prevented dexamethasone-induced apoptosis in scramble-
silenced MLO-Y4 osteocytic cells, and in HeLa cells [which lack
endogenous Cx43 (Plotkin et al., 2002)] transfected with Cx43, but
not in Cx43def cells or in vector-transfected HeLa cells (Fig. 4F). The levels
of dead cells were quantified 7 h after all detached cells were removed
from the cultures, unlike the ones shown in previous figures, which were
measured at least 24 h after washing the cultures to remove dead cells.
Nevertheless, we still detected an increase in the percentage of dead
cells in vehicle-treated Cx43 silenced MLO-Y4 cells compared to vehicle-
treated scramble shRNA cells (~ 6% vs. ~ 4%).
Fig. 3 Deletion of miR21 is sufficient to induce osteocyte apoptosis and increase PTEN levels in bone. (A) MLO-Y4 osteocytic cells were transfected with the indicated
oligonucleotides, and cell death was assessed by Trypan blue uptake (n = 6). *P < 0.05 vs. corresponding scramble shRNA cells, by t-test. (B) Neonatal calvariae from
miR21fl/fl mice at 5 days of age were treated with adenovirus-Cre to delete miR21 gene. miR21 levels corrected by miR135 measured by qPCR. Representative images of viral
infection efficiency under fluorescence microscope in adenovirus-GFP calvariae and adenovirus-Cre (without GFP expression) calvariae (inset) are shown. Scale bar indicates
100 lm. (C) TEM images of neonatal calvariae from miR21fl/fl mice treated with adenovirus-GFP (control) or adenovirus-Cre. Images are representative of three samples.
Asterisks indicate empty lacunae, and arrows point at the endoplasmic reticulum. Scale bars indicate 2 lm. (D) Gene expression measured in calvaria by qPCR and corrected
by GAPDH (n = 3). Bars represent mean  SD. (E) PTEN expression in calvaria was assessed 48 h after miR21 deletion by Western blotting and normalized to lamin B levels
(n = 3). (B–E) *P < 0.05 vs. corresponding cells infected with adenovirus-GFP, by t-test.
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Deletion of Cx43 increases the release of pro-
osteoclastogenic cytokines by osteocytic cells
We next examined the molecular basis for osteoclast recruitment
induced by Cx43 deficiency. As found before (Bivi et al., 2012), silencing
Cx43 from MLO-Y4 cells results in increased RANKL and reduced
oseoprotegerin (OPG) levels (Fig. 5A). Similar results were found in old
mice (Cao et al., 2003; Almeida et al., 2007a). Inhibition of apoptosis
with DEVD reversed the increase in RANKL mRNA levels, but did not
change OPG mRNA levels in Cx43def cells. Furthermore, removal of
miR21 from bones increased RANKL, but did not alter OPG mRNA levels
(Fig. 5B). Taken together, these pieces of evidence suggest that the
increase in RANKL but not the reduction in OPG levels in the absence of
Cx43 is due to increased osteocyte apoptosis downstream of miR21
downregulation.
HMGB1, a ubiquitously expressed molecule, has been shown to
increase in the circulation in rats with aging (Fonken et al., 2016;
Terrando et al., 2016) and to increase RANKL expression in osteocytic
cells (Yang et al., 2008). However, we did not find changes in HMGB1
levels in the serum of old mice (Fig. S2). Silencing of Cx43 in MLO-Y4
osteocytic cells resulted in a 77% decrease in the amount of intracellular
HMGB1, and a 480% increase in the levels of the cytokine in the
conditionedmedia, suggesting increased release of HMGB1 (Fig. 5C). We
also detected a tendency toward HMGB1 increase in serum from Cx43DOt
mice, although it did not reach significance (Fig. S2).
Inhibition of apoptosis with DEVD or blockage of HMGB1 activity with
glycyrrhizic acid (GA) reversed the increase in RANKL mRNA levels, and
the release of RANKL to the extracellular media (Fig. 5D). In addition, the
levels of HMGB1 in conditioned media were reversed to control levels in
cells treated with DEVD and attenuated in cells treated with GA (Fig. 5E).
GA binds to HMGB1 and blocks HMGB1 chemoattractant and mitogenic
activities (Mollica et al., 2007) and, unlike its analog glycyrrhetinic acid,
does not inhibit connexin channel activity in MLO-Y4 osteocytic cells
(Plotkin et al., 2002). Addition of a neutralizing anti-HMGB1 antibody to
Cx43-silenced MLO-Y4 cells partially reversed the increase in RANKL
mRNA without affecting OPG levels, resulting in a significant decrease in
Fig. 4 Cx43-deficiency and aging leads to disruptions in PTEN/pAkt pathway and abolishes the anti-apoptotic effect of IGF-1. (A) PTEN expression in ulna from Cx43fl/fl and
Cx43DOt mice at 4.5 months of age assessed by Western blotting and normalized by lamin B (n = 3). *P < 0.05 vs. Cx43fl/fl mice, by t-test. Bars represent mean  SD. (B,C)
PTEN and phosphorylated Akt (pAkt) were analyzed in MLO-Y4 osteocytic cell lysates by Western blotting (n = 3–4). *P < 0.05 vs. corresponding scramble shRNA cells, by t-
test. (D) MLO-Y4 osteocytic cells were treated with vehicle or the PTEN inhibitor SF1670 for 30 min, the media were changed, and the cells were cultured for additional
24 h. Percentage of dead cells was assessed by Trypan blue uptake (n = 3). *P < 0.05 vs. corresponding scramble shRNA cells by two-way ANOVA. (E) pAkt and total Akt
were analyzed by Western blotting (n = 3). *P < 0.05 vs. corresponding scramble shRNA cells, by t-test. (F) MLO-Y4 osteocytic cells expressing or not Cx43 and HeLA cells
transfected with empty vector or Cx43 together with IGF receptor 1 and nGFP were treated with vehicle or IGF-1 for 1 h, followed by 6-h treatment with vehicle or
dexamethasone. Cell death was assessed by Trypan blue uptake (for MLO-Y4 cells) or by nuclear morphology (for HeLa cells) (n = 3). *P < 0.05 vs. vehicle-treated cells for
each condition, by two-way ANOVA.
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RANKL/OPG ratio, compared to cells treated with nonimmune IgG
(Fig. 5F).
Increased osteoclastogenesis is inhibited by blocking
apoptosis of Cx43-deficient MLO-Y4 osteocytic cells
We next investigated whether deletion of Cx43 in osteocytic cells
resulted in enhanced osteoclastogenic potential. Increased number of
multinucleated TRAP-positive osteoclasts was observed in co-cultures of
nonadherent bone marrow cells (osteoclast precursors) with Cx43-
silenced MLO-Y4 cells (Fig. 6A). In addition, conditioned media from
cells silenced for Cx43 induced more osteoclasts than media from
control cells (Fig. 6B), indicating that factors secreted by the osteocytic
cells are responsible for the increased osteoclast differentiation. Inhibi-
tion of apoptosis of Cx43def cells with DEVD reduced the osteoclasto-
genic potential of the conditioned media, which was now similar to
conditioned media from scramble shRNA-treated cells. Furthermore, the
expression of osteoclast markers was increased in bone marrow cells
Fig. 5 Increased osteocyte apoptosis with reduced Cx43 and miR21 leads to increased RANKL/OPG ratio. (A) Expression of the indicated genes and in MLO-Y4 cells
expressing or lacking Cx43 treated with vehicle or DEVD for 1 h and measured 24 h later. Bars represent mean  SD (n = 6). *P < 0.05 vs. corresponding shRNA scramble
cells and #P < 0.05 vs. vehicle-treated Cx43 shRNA cells by two-way ANOVA. (B) mRNA levels for the indicated genes in calvaria from miR21fl/fl mice treated with adenovirus-
GFP or adenovirus-Cre (n = 3). Bars represent mean  SD (n = 3). *P < 0.05 vs. adenovirus-GFP-treated bone, by t-test. (C) HMGB1 protein expression corrected by b-actin
measured in cell lysate and conditioned medium of MLO-Y4 osteocytic cells by Western blotting (n = 3). (D,E) mRNA levels for RANKL and concentration of sRANKL and
HMGB1 in conditioned media from MLO-Y4 cells expressing or not Cx43, and treated with vehicle, DEVD or GA were measured by qPCR and ELISA, respectively (n = 3). (F)
Expression of the indicated genes corrected by GAPDH in MLO-Y4 cells expressing or not Cx43 and treated with nonimmune (ni) IgG or neutralizing anti-HMGB1 antibodies
for 24 h (n = 6). *P < 0.05 vs. corresponding shRNA scramble cells and #P < 0.05 vs. ni IgG-treated Cx43 shRNA cells by two-way ANOVA.
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treated with conditioned media from Cx43-deficient cells, whereas their
levels were similar to controls when the conditioned media was obtained
from cells treated with DEVD (Fig. 6C). Treatment with boxA, which
antagonizes HMGB1 binding to its receptor RAGE (Yang et al., 2004),
decreased osteoclast formation induced by conditioned media from
Cx43-deficient cells (Fig. 6D), suggesting the HMGB1 released by
osteocytic cells is responsible for the increase in osteoclast differentiation
via activating RAGE.
Discussion
In the current study, we dissected the molecular signaling pathway
underlying osteocyte apoptosis triggered in the absence of osteocytic
Cx43 and by aging (Fig. 6E). In addition, we unveiled the molecular link
between osteocyte apoptosis and targeted osteoclastic bone resorption.
Based on our evidence, we propose that old age and absence of
osteocytic Cx43 cause decreased miR21 levels, and the associated
increased PTEN protein levels and decreased Akt activation, resulting in
osteocyte apoptosis. Apoptotic osteocytes release more HMGB1, which
in turn activates RAGE in osteoclast precursors to induce osteoclast
differentiation.
Similar to the current report, immunohistochemistry studies showed
that Cx43 expression in osteocytes decreases in old mice (Kar et al.,
2013). On the other hand, the expression of Cx43 is not decreased in
osteoblastic cells isolated from old rats (Genetos et al., 2012). This
evidence suggests that Cx43 expression decreases in osteocytes but not
in osteoblasts with aging.
Deletion of Cx43 from osteocytes in mice and stable silencing of Cx43
in MLO-Y4 osteocytic cells results in spontaneous cell death by a
caspase-3-dependent mechanism, demonstrating the requirement of
Cx43 in the survival of osteocytes [Bivi et al. (2012) and this report].
Unlike the studies in mice lacking Cx43 (Bivi et al., 2012; Lloyd et al.,
2013), ubiquitous expression of a mutated Cx43 (G60S/+ mice) does not
result in increased osteocyte apoptosis, changes in osteocyte number or
altered number of empty lacunae (Zappitelli et al., 2013). This evidence
suggests that the level and activity of Cx43 in the Cx43 G60S/+ mice is
sufficient to maintain osteocyte viability and that the phenotype of the
G60S/+ mice is likely due to the role of Cx43 in early osteoblastic cells
and their progenitors.
The survival effect of Cx43 does not involve the scaffold or regulatory
domains present in Cx43 C-terminus. This is consistent with our previous
study showing that expression of a truncated Cx43 lacking the C-
terminus domain restores osteocyte viability in mice lacking Cx43 in
osteocytes (Pacheco-Costa et al., 2015). Similarly, the altered bone
material mechanical properties, with decreased stiffness, of mice lacking
osteocytic Cx43 are reversed by the truncated Cx43. Nevertheless, our
in vitro data, together with our previous in vivo study (Pacheco-Costa
et al., 2015) and a recent report in male mice expressing only the
truncated Cx43 (Moorer et al., 2017), suggest that the trans-membrane
and cytoplasmic amino-terminal domains are sufficient to maintain
osteocyte viability and preserve normal cortical bone geometry and
material properties. Future studies using mice overexpressing Cx43 in
osteocytes (currently under development in our laboratory) will allow us
to determine whether maintenance of Cx43 levels reverses the increased
osteocyte apoptosis and, at least partially, the skeletal phenotype of old
mice.
The underlying molecular mechanisms that lead to increased osteocyte
apoptosis in the absence of Cx43 and in old age remained unclear. We now
propose the existence of a signaling cascade that maintains cell viability
through the regulation of miR21 downstream of Cx43 (Fig. 6E). Although
we also found that miR218 levels are increased in Cx43def cells, this increase
was not reproduced in bones from old mice or mice lacking Cx43 in
osteocytes, suggesting that whereas miR21 is regulated by Cx43, signals
other than Cx43 are involved in miR218 regulation in vivo.
Several pieces of evidence support the role of miR21 on osteocyte
apoptosis. First, both Cx43DOt mice and Cx43-deficient osteocytic cells
exhibit accelerated cell death and express lower levels of miR21, a pro-
survival miR (Garzon et al., 2009). Further, miR21 deletion by aden-
ovirus-Cre in miR21fl/fl calvaria bones increases the expression of
apoptosis-related genes; and reducing miR21 expression using oligonu-
cleotide inhibitors induces apoptosis of control osteocytic cells. Con-
versely, a miR21 oligonucleotide mimic attenuates Cx43-deficient
osteocyte apoptosis, supporting the idea that miR21 reduction causes
the increased osteocyte apoptosis in the absence of Cx43. Consistently,
the expression of both Cx43 and miR21 is reduced in old bones,
suggesting that the decreases in Cx43 and miR21 levels contribute to the
decreased osteocyte viability in old age. Although the mechanism by
which reduced Cx43 expression leads to decreases in miR21 levels is not
known, these two genes are not located in the same gene locus
(Kozomara & Griffiths-Jones, 2014), excluding the possibility that a
deletion of one gene removes the other one.
In addition to inducing apoptosis, miR21 deletion increases RANKL
expression. The regulation of RANKL expression in Cx43-deficient
osteocytes could be a consequence of increased apoptosis in the
absence of miR21, or to the lack of direct actions of miR21 on the
RANKL gene. However, miR21 deletion reduces RANKL expression in
multiple myeloma-exposed bone marrow cells (Pitari et al., 2015),
suggesting that direct actions of the miR on gene expression are not the
cause of increased RANKL levels in our study. It is therefore likely that the
changes in RANKL expression in cells in which miR21 was deleted are a
consequence of increased apoptosis. Future studies are needed to
further support this conclusion.
The mechanism by which old age leads to increased osteocyte
apoptosis is not completely understood. Previous studies showed that
the survival effect of IGF-1 is reduced in osteoblastic cells isolated from
old (24-month-old) compared to young (1.5-month-old) and adult (6-
month-old) mice, even though the levels of the IGF-1 receptor are
increased in the older mice (Cao et al., 2007). The resistance of bone
Fig. 6 Blockage of apoptosis in Cx43-silenced MLO-Y4 osteocytic cells reduces their osteoclastogenic potential. (A) Bone marrow cells isolated from C57Bl/6 mice and co-
cultured with MLO-Y4 osteocytic cells expressing or not Cx43 for 7 days. Multinucleated (≥ 3 nuclei) osteoclasts were enumerated. Bars represent mean  SD (n = 4).
*P < 0.05 vs. shRNA scramble cells by t-test. (B,C) Bone marrow cells were cultured in the presence of conditioned media from MLO-Y4 osteocytic cells expressing or not
Cx43 and treated for 1 h with vehicle or DEVD. (B) Multinucleated osteoclasts and representative images of cultured osteoclasts stained by TRAP and (C) mRNA expression
for the indicated genes assessed by qPCR were measured after 7-day culture. Bars represent mean  SD (n = 4). *P < 0.05 vs. vehicle-treated shRNA scramble cells, and
#P < 0.05 vs. vehicle-treated Cx43 shRNA cells, by two-way ANOVA. Scale bars indicate 200 lm. (D) Multinucleated osteoclasts were enumerated after treatment of
nonadherent bone marrow cells with conditioned media from MLO-Y4 osteocytic cells expressing or not Cx43 in the presence of vehicle or boxA. Bars represent mean  SD
(n = 4). *P < 0.05 vs. corresponding shRNA scramble cells, by two-way ANOVA. Representative images of cultured osteoclasts stained by TRAP are shown. Scale bars
indicate 100 lm. (E) Working model showing decreased osteocytic Cx43 leads to a reduction in miR21 levels which, in turn, leads to an increase in PTEN levels and
consequently a reduction in Akt activation. Decreased Akt activity leads to increased expression of the apoptosis-related genes p27, FoxO3, and GADD153 resulting in
caspase-3-mediated apoptosis. At the same time, apoptotic osteocytes release RANKL and HMGB1, which induce osteoclast differentiation and recruitment.
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marrow cells from old mice to IGF-1 effect was associated with reduced
activation of Akt, a known mediator of survival induced by the cytokine
(Ma et al., 2011). We now propose that reduced response to IGF-1 in old
animals is due to decreased Cx43/miR21 levels, counteracting the effect
of IGF-1 on the PTEN/pAkt pathway. Consistent with this notion, IGF-1
prevents apoptosis of osteoblastic cells (Hill et al., 1997; Grey et al.,
2003) and Cx43 is required for the survival effect of IGF-1 in
cardiomyocyte precursors (Lu et al., 2009).
Osteocyte apoptosis has been shown to precede and to be associated
with increased targeted recruitment of osteoclasts along adjacent bone
surfaces in several animal models [recently reviewed by us (Plotkin, 2014;
Plotkin & Bellido, 2016)]. Consistently, we showed that osteocyte-specific
Cx43 deletion leads to accumulation of apoptotic osteocytes, and an
associated increase in osteoclasts in some adjacent areas on endocortical
bone surfaces (Bivi et al., 2012). Additionally, Cx43-deficient osteocytic
cells exhibit an increase in the RANKL/OPG ratio, facilitating osteoclast
formation. However, increased populations of osteocytes with reduced
OPG levels are present even in areas lacking osteoclasts in Cx43DOt mice,
suggesting that apoptotic osteocytes release other signals that are
required for osteoclast recruitment. The specific molecules underlying this
increased osteoclast recruitment were heretofore unknown. We now
show that Cx43-deficient osteocytes release elevated levels of the pro-
inflammatory cytokine HMGB1. Similarly, induction of MLO-Y4 osteo-
cytic cell apoptosis with TNF-a/cycloheximide increases HMGB1 release
(Yang et al., 2008). However, in Yang’s study, addition of HMGB1 to the
cells increased Akt phosphorylation, rather than decreased it, as reported
here. This evidence suggests that the changes in Akt activity in the Cx43-
deficient cells are not a response to the released HMGB1, but the result of
the increase in PTEN levels downstream of miR21 downregulation.
We also found that inhibition of osteocyte apoptosis with DEVD or
treatment with a HMGB1 neutralizing antibody or GA, an inhibitor of
HMGB1 action (Zhang et al., 2015), reduces RANKL expression in Cx43-
deficient cells. This is consistent with previous work showing that apoptotic
MLO-Y4 osteocytic cells release HMGB1 (Charoonpatrapong et al., 2006;
Klune et al., 2008). Further, HMGB1 is chemotactic for osteoclasts and
triggers osteoclastogenesis by activating RAGE (Taniguchi et al., 2007; Zhou
et al., 2008; Yang et al., 2013). Consistently, inhibition of apoptosis
prevents RANKL and HMGB1 release and attenuates the enhanced
osteoclastogenesis andosteoclastmarker expression inducedbyconditioned
media from Cx43-deficient osteocytes. In addition, the HMGB1-RAGE
receptor antagonist boxA (Yang et al., 2004) blocks osteoclastogenesis
inducedby conditionedmedia fromCx43-deficientosteocytes.However,we
could not detect systemic changes in HMGB1 levels in Cx43-deficient or old
mice. Therefore, our results suggest that HMGB1 released by Cx43-deficient
osteocytes in their vicinity enhances osteoclastogenesis by increasing RANKL
in osteocytes and, at the same time, directly stimulating osteoclast precursor
differentiation at least partially through activation of RAGE. Future studies
will allow us to further elucidate the mechanisms by which apoptotic
osteocytes inCx43DOt andoldmice releaseHMGB1and the role of the RAGE
and TLR4 receptors on the induction of osteoclast recruitment.
In summary, we propose that gap junction communications through
Cx43 channels maintain osteocyte viability via downstream regulation of
miR21, leading to the subsequent inhibition of PTEN activity and
preservation of the Akt survival pathway (Fig. 6E). Additionally, our
findings support a model where reduced Cx43 levels in osteocytes in old
animals lead to apoptosis and the release of RANKL and HMGB1, which
signal osteoclasts to increase resorption along associated bone surfaces.
We therefore identified a novel Cx43/miR21/HMGB1/RANKL pathway
mediated by gap junction communications in osteocytes that could be
targeted to treat bone fragility with aging.
Experimental procedures
Mice
C57BL/6 female mice were purchased from National Institute on Aging
and sacrificed at 4, 12, 18, 21, and 24 months of age. To delete Cx43
specifically in osteocytes, mice were generated using the Cre/LoxP
system (Bivi et al., 2012). Cx43fl/fl mice were crossed with mice
harboring DMP1-8 kb-Cre, which express Cre-recombinase under con-
trol of a DNA fragment containing 8 kb of the murine dentin matrix
protein 1 promoter (named Cx43DOt). The mouse strain with engineered
lox cassettes on both sides of the mmu-miR-21 genomic locus (named
miR21fl/fl) was generated by Dr. Ivan through Ozgene Pty Ltd, a service
provider of genetically modified mice (Perth, Australia). All mice used
were maintained in a C57BL/6 background. The protocols involving mice
were approved by the Institutional Animal Care and Use Committee of
Indiana University School of Medicine.
Cell culture, silencing, and transient transfections
MLO-Y4 osteocytic and Ob-6 osteoblastic cells were silenced using
short hairpin (sh)RNA Lentiviral Particles (Sigma-Aldrich Chemical Co.,
St. Louis, MO, USA), as previously reported (Plotkin et al., 2008; Bivi
et al., 2011), and cultured as previously described. The efficiency of
deletion was determined by quantifying Cx43 protein and mRNA
levels by Western blotting and by qPCR, respectively. All samples from
in vitro studies were collected 24 h after seeding the cells or 48 h
after transfection, unless otherwise indicated. The plasmid encoding
the full-length rat Cx43 (abbreviated as Wt) was provided by R.
Civitelli (Washington University, Saint Louis, MO) (Lecanda et al.,
1998). The mutant Cx43 truncated at amino acid 245 (abbreviated as
Cx43D245) (Zhou et al., 1999) and the Cx43 carboxy-terminal tail
(abbreviated as Cx43C-tail) (Zhou et al., 1999) were provided by B.
Nicholson (University of Texas, Santo Antonio, TX). Cx43 lacking seven
residues from the internal loop at positions 130–136 (abbreviated as
Cx43D130) was provided by V.A. Krutovskikh (International Agency for
Research on Cancer, Lyon, France) (Krutovskikh et al., 1998). Cx43Cys-
less, which has all cysteine sites on the two extracellular loops replaced
by alanine (abbreviated as Cx43Cys-less), was provided by G.M. Kidder
(University of Western Ontario, Ontario, Canada) (Tong et al., 2007).
All of the constructs used in this study are of rat origin and have been
shown to produce functional proteins. pcDNA3.1 empty vector was
used as control (Invitrogen, Grand Island, NY, USA). MLO-Y4
osteocytic cells were transiently transfected with different DNA
constructs together with nuclear GFP using Lipofectamine Plus
(Invitrogen) reagent with 0.1 lg cm2 as described previously (Bivi
et al., 2011). Apoptosis was assessed 48 h after transfection by
quantification of cells exhibiting nuclear fragmentation and chromatin
condensation under an EVOS fluorescence microscope system (Life
Technologies, Carlsbad, CA, USA).
HeLa cells (2 9 104cells cm2) were transiently transfected with
either empty vector or rat Cx43 together with IGFR1 and nuclear GFP
using Lipofectamine Plus, as published (Plotkin et al., 2002), and
apoptosis was assessed as indicated below.
Western blotting analysis
Whole protein extracts from MLO-Y4 osteocytic cells or from bone were
prepared as published (Plotkin et al., 2011; Bivi et al., 2012). To
determine the levels of HMGB1 on culture supernatants, proteins were
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concentrated 109 by precipitation using trichloroacetic acid (5:1). Protein
lysates were separated on 10% SDS–PAGE gels and electrotransferred to
polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA).
These membranes were incubated in blocking solution (5% nonfat milk)
for 30 min and probed with primary antibodies diluted 1:1000 in 5%
nonfat milk against a monoclonal anti-PTEN (Sc-7974), polyclonal anti-
GADD153 (Sc-575), anti-lamin B (Sc-6217) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), monoclonal anti-Akt (2920), anti-phosphorylated
Akt at serine 473(4060) (Cell Signaling Technology, Danvers, MA, USA),
anti-cleaved caspase-3 (Asp175) (PA5-23921; Thermo Fisher Scientific,
Rockford, IL, USA), anti-connexin43 (C6219) and anti-b-actin (A5316)
(Sigma-Aldrich), and anti-HMGB1 (ab18256) (Abcam, Cambridge, MA,
USA) overnight at 4 °C, followed by corresponding secondary antibodies
conjugated with horseradish peroxidase in 5% nonfat milk (Santa Cruz
Biotechnology) for 4 h at room temperature. After rinsing with TBS-T, the
membranes were developed with an enhanced chemiluminescence
Western blotting substrate kit (Pierce Biotechnology Inc., Rockford, IL,
USA). Bands were detected, and their intensity was quantified using the
TotalLab TL 100 software (Nonlinear Dynamics Ltd., Durham, NC, USA).
RNA extraction and real-time PCR (qPCR)
Total RNAwas isolated and purified using TRIzol (Invitrogen), as published
(Pacheco-Costa et al., 2014). Reverse transcription was performed using
a high-capacity cDNA kit (Applied Biosystems, Foster City, CA, USA).
qPCR was performed using the Gene Expression Assay Mix TaqMan
Universal Master Mix with an ABI 7900HT real-time PCR system. The
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) was used. Primers and probes were commercially available
(Applied Biosystems) or were designed using the Assay Design Center
(Roche Applied Science, Indianapolis, IN, USA). To evaluate miRNA’s
expression level, total RNA was isolated and purified using TRIzol reagent
and 10 ng was reversely transcribed to cDNA using TaqMan miR reverse
transcription kit (Applied Biosystems, Carlsbad, CA, USA) to detect and
quantify maturemiR21 (assay ID: 000397), miR18 (assay ID: 000521), and
miR135 (assay ID: 001230). The reaction mixtures were incubated at
16 °C for 30 min, 42 °C for 30 min, 85 °C for 5 min, and 4 °C for 30 s.
The values were normalized for housekeeping miR135. Relative expres-
sion was calculated using the ΔCt method.
IGF-1, DEVD, and PTEN inhibitor treatment
MLO-Y4osteocytic cells orHeLa cellswere treatedwithvehicleor5 ng mL1
IGF-1 for 1 h, followed by 6-h treatment with vehicle or 106 M
dexamethasone. In addition, in a parallel experiment, MLO-Y4 osteocytic
cells were treated with vehicle or 1 lM SF1670 (Abcam Biochemical,
Cambridge,MA, USA.) for 30 min and then cultured for 24 h. For apoptosis
inhibition, cells were treated for 1 h with 50 nM Ac-DEVD-CHO (DEVD,
Biotium, Inc., Hayward, CA, USA), a caspase-3/7 inhibitor, which was then
removed and cells were cultured in freshmedia for 24 h, or treated for 24 h
with 50 nM DEVD. To determine the percentage of dead cells, supernatant
was removed and cells were re-suspended in 25 lL of 19 Trypan blue. Ten
microliters of the cell suspension were transferred to a hemocytometer, and
the number of viable cells (clear, transparent) and dead (blue) was counted.
Dataare reportedaspercentageofdeadcells.Cellswere transfectedwith the
indicated constructs together with nuclear GFP to assess the nuclear
morphologyonly in transfectedcells. Forty-eighthours after transfectioncells
were washed to remove dead cells, and treated with 5 ng mL1 IGF-1 for
1 h, followed by 106 M dexamethasone. Cells were fixed 6 h later, and the
prevalence of apoptotic cells exhibiting chromatin condensation and nuclear
fragmentation was assessed under fluorescence microscopy. Data are
reported as percentage of apoptotic cells.
miR array analysis
The effect of Cx43 silencing on miRNA levels in MLO-Y4 osteocytic cells
was assessed using the Apoptosis-Associated miRNA Plate Array, as
described by the manufacturer (Signosis Inc., Santa Clara, CA, USA; cat.
# MA-1002). The values were normalized for U6 RNA.
miR silencing and overexpression
MLO-Y4 osteocytic cells silenced or not for Cx43 were plated at the
density of 2 9 104 cells cm2 on 48-well plates coated with type I rat
tail collagen and cultured overnight. Cells were transiently transfected
using Lipofectamine RNAiMAX reagent (Invitrogen) containing miRIDIAN
negative control inhibitor, miR21 inhibitor, negative control mimic, or
miR21 mimic (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) at a final
concentration of 0.1 nM in medium without serum and penicillin/
streptomycin for 6 h. Next, medium 29 concentrated was added to each
well and then cultured overnight. Medium was changed to a regular
growing medium, and cells were then cultured for an additional 24 h
before measuring cell death by Trypan blue uptake. miR21 levels were
decreased by 60% in MLO-Y4 scramble cells and by 91% in MLO-Y4
Cx43 shRNA cells treated with miR21 inhibitor, as measured by qPCR.
miR21 levels were increased by 44% in MLO-Y4 scramble cells and
234% in MLO-Y4 Cx43 shRNA cells treated with the miR21 mimic.
Viral infection of calvaria bone ex vivo
Calvariae ofmiR21fl/flmicewere harvested at 5 days of age, and two 5-mm
pieces of the bone were removed using a biopsy punch (Integra
LifeSciences Corporation, Plainsboro, NJ, USA). Samples were washed in
PBS and incubated in a 96-well plate with a-minimal essential medium
supplemented with 10% FBS and 1% penicillin/streptomycin for 6 h.
Bones were then treated with 2.5 lL per well of control adenovirus
(Adeno-GFP, cat.#1060) or Cre-recombinase virus (cat.#1700) (Vector
BioLabs, Malvern, PA, USA) diluted in serum-free a-minimal essential
medium in a final volume of 45 lL overnight. Next, media were removed
and samples were washed twice with PBS before adding a-minimal
essential medium supplemented with 10% FBS and 1% penicillin/
streptomycin and cultured for additional 48 h at 37% and 5% CO2.
mRNAwas quantified by qPCR and protein quantified byWestern blotting.
Transmission electron microscopy (TEM)
Calvaria bones from miR21fl/fl mice treated with adenovirus (Adeno-
GFP, cat.#1060) or Cre-recombinase virus were processed for TEM as
previously published (Bivi et al., 2012). Briefly, bones were decalcified
and postfixed in 2% paraformaldehyde/2% glutaraldehyde in 0.1 M
cacodylate buffer for 1 h, followed by 1 h-treatment with 1%
osmium tetroxide in 0.1 M cacodylate buffer. After standard dehydra-
tion and embedding in Embed 812 (Electron Microscopy Sciences,
Hatfield, PA, USA), the blocks were sectioned at 85 nm and placed
on copper grids, stained with uranyl acetate, and viewed on a Tecnai
G2 12 Bio Twin electron microscope (FEI, Hillsboro, OR, USA) at the
Electron Microscopy Center of the Department of Anatomy and Cell
Biology (Indiana University School of Medicine). Digital images were
taken with an Advanced Microscope Techniques (Danvers, MA, USA)
CCD camera.
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Osteoclastogenesis in co-cultures and with conditioned
medium
Bone marrow cells were isolated from C57Bl/6 mice by flushing the bone
marrow out with a-minimal essential medium supplemented with 10%
FBS and 1% penicillin/streptomycin and cultured for 24–48 h. Next,
nonadherent were collected and 2 9 105 cells cm2 were seeded on top
of MLO-Y4 osteocytic cells silenced or not for Cx43. Cells were cultured in
the presence of 10 nM 1.25(OH)2 vitamin D3 and 1 lM PGE2. Medium
was changed every 2 days for 5 days, as previously published (Miyazaki
et al., 2003). The conditioned medium from MLO-Y4 osteocytic cells
silenced or not for Cx43 was collected after 24 h-culture and then
concentrated 49 using centricon filters (10 kDa cutoff) (EDM Millipore).
Media was diluted 1:4 and added to 48-well plate containing
2 9 105 nonadherent cells cm2 with 40 ng mL1 RANKL and
20 ng mL1 M-CSF (Pacheco-Costa et al., 2014). Growing medium that
had not been in contact with the cells was used as control. Osteoclasts
exhibiting 3 or more nuclei were enumerated after staining for TRAPase
using a commercial kit (Sigma-Aldrich). Images were acquired using a
Zeiss Axiovert 35 microscope equipped with a digital camera Carl Zeiss
Microimaging Inc., Thronwood, NY, USA.
Neutralization of HMGB1 in cell cultures
MLO-Y4 osteocytic cells silenced or not for Cx43 were plated at the
density of 2 9 105 cells cm2 on six-well plates coated with type I rat
tail collagen and cultured overnight. Cells were either treated with
1 mg mL1 GA (Zhang et al., 2015) or with 0.5 lg mL1 nonimmune
(ni) rabbit IgG (Abcam, cat.# ab171870) or neutralizing rabbit anti-
HMGB1 (Abcam, cat.# ab18256) antibodies for 24 h and then concen-
trated 49 using centricon filters (10 kDa cut off) (EDM Millipore). For
cultures with immunoglobulins, conditioned media were incubated with
10 lL mL1 protein A agarose (Roche Applied Science, cat.#
11719408001) overnight at 4 °C to remove the immunoglobulins.
One molar HEPES was then added to IgG-depleted conditioning media,
which was then aliquoted and stored at 80 °C until used.
Soluble RANKL, OPG, and HMGB1 levels in conditioned media
Conditioned media from MLO-Y4 cells were collected, aliquoted, and
stored at 80 °C until used. RANKL, OPG, and HMGB1 protein levels in
the supernatants were determined using Quantikine Mouse RANKL
Immunoassay (R&D Systems, Inc., Minneapolis, MN, USA, cat.# MTR00),
Quantikine Osteoprotegerin Immusoassay (R&D Systems, Inc., cat.#
MOP00), or HMGB1 Immunoassay (IBL International, Hamburg, Ger-
many, cat.# ST51011), respectively.
Statistical analysis
Data were analyzed using SigmaPlot (Systat Software Inc., San Jose, CA,
USA). All values are reported as the mean  standard deviation. Differ-
ences were evaluated either by one- or two-way ANOVA, with post hoc
analysis using Tukey Method or by Student’s t-test, as appropriate.
Differences were considered significant when P < 0.05.
Additional methods are included in Data S1 under supplementary
material.
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